Sex: F
Vaccine: UNK, VARZOS
Symptoms: Impaired healing, Osteoporosis, Product dose omission issue, Underdose
Clinical narrative: underdose/taking Nucala only once in every 8 weeks; missed dose/stopped Nucala AI; osteoporosis/ Nucala causing osteoporosis or helping it along; slow healing of first fracture left arm; This case was reported by a consumer via call center representative and described the occurrence of osteoporosis in a adult female patient who received mepolizumab (Nucala) solution for injection in pre-filled pen for drug use for unknown indication.   Co-suspect products included mepolizumab autoinjector device (Nucala Autoinjector Device) administration system for drug use for unknown indication and Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included fall and arm fracture (left arm fracture). Concurrent medical conditions included asthma. Concomitant products included zileuton (Zyflo).   In March 2019, the patient started Nucala at an unknown dose and Nucala Autoinjector Device. On an unknown date, the patient received Shingles vaccine (unknown). In 2019, an unknown time after starting Nucala and Nucala Autoinjector Device and unknown after receiving Shingles vaccine, the patient experienced healing delayed. In August 2021, the patient experienced osteoporosis. On an unknown date, the patient experienced underdose and missed dose. Nucala was interrupted (Dechallenge was unknown). On an unknown date, the outcome of the osteoporosis, healing delayed, underdose and missed dose were unknown.   The reporter considered the osteoporosis to be related to Nucala and Nucala Autoinjector Device. It was unknown if the reporter considered the healing delayed to be related to Nucala, Nucala Autoinjector Device and Shingles vaccine. It was unknown if the reporter considered the osteoporosis to be related to Shingles vaccine.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Linked case(s) involving the same patient:  US2022AMR193606   GSK receipt date: 27 Dec 2022, 27 Dec 2022 Reporter comments: Patient was the reporter. Nucala used by patient with frequency every 8 weeks. The consumer stated, she had been on Nucala PI since Mar 2019. The patient stated, she was diagnosed with osteoporosis on Aug 2021, after stating Nucala. The patient stated because of insurance and health coverage patient was taking Nucala only once in every 8 weeks and doing well on this regimen. The patient stated in Mar 2019 before starting Nucala she had fallen and fractured her left arm and the doctor had stated she was healing fast. Shortly after the fracture she had started Nucala and the doctor stated since she started Nucala, the left arm bone was healing very slowly, which they attributed to Nucala. The patient stated after starting Nucala AI, she had stopped Nucala AI for three months to receive the shingles vaccine. Consented to follow up. The patient used to work for Pfizer, so she understand that a lot of things were brushed under the rug. She believed that drug was causing osteoporosis, and or at least kind of helping it along. So, she thought that GSK should look into that, and it makes perfect sense because of eosinophils. They were needed for bone repair, and the drug suppresses eosinophils, so obviously she thought it was an area need to look at the data more.